Enavogliflozin API | SGLT2 Inhibitor API Manufacturer & Supplier

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Enavogliflozin API

Enavogliflozin API is a synthetic small-molecule pharmaceutical ingredient belonging to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class. It is an orally active antidiabetic drug developed for the treatment of type 2 diabetes mellitus. Enavogliflozin selectively inhibits SGLT2 in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion.

Enavogliflozin is also known by the development code DWP16001. It has been developed as a once-daily oral SGLT2 inhibitor and is marketed in South Korea under the brand name Envlo.

What is Enavogliflozin?

Enavogliflozin is a selective SGLT2 inhibitor that works primarily in the kidneys. By inhibiting SGLT2, it decreases the reabsorption of filtered glucose and promotes glucose elimination through urine. This mechanism helps reduce blood glucose levels in patients with type 2 diabetes.

Enavogliflozin has the molecular formula C₂₄H₂₇ClO₇ and a molecular weight of approximately 462.92 g/mol.

Enavogliflozin API Manufacturer & Supplier

Swapnroop Drugs and Pharmaceuticals provides Enavogliflozin API for qualified pharmaceutical manufacturing, formulation development and pharmaceutical research requirements.

Enavogliflozin is a specialized antidiabetic API suitable for pharmaceutical companies and formulation developers working with SGLT2 inhibitor products.

Mechanism of Action

Enavogliflozin selectively inhibits sodium-glucose cotransporter 2 (SGLT2), which is primarily responsible for glucose reabsorption in the proximal renal tubules. SGLT2 inhibition reduces renal glucose reabsorption and increases urinary glucose excretion, thereby lowering blood glucose levels.

Pharmaceutical Applications

Enavogliflozin is associated with:

  • Type 2 diabetes mellitus treatment
  • SGLT2 inhibitor formulations
  • Antidiabetic drug development
  • Diabetes-focused pharmaceutical research
  • Oral pharmaceutical formulations
  • Pharmaceutical formulation development

Quality & Pharmaceutical Standards

Enavogliflozin API can be evaluated using validated analytical procedures for identification, assay, related substances, residual solvents, water content, residue on ignition, elemental impurities and other applicable quality attributes.

Numerical acceptance criteria should be taken from the current approved manufacturer specification or applicable regulatory/pharmacopoeial documentation rather than using generic limits.

Detailed Specifications

Parameter Specification
Appearance White to off-white crystalline powder
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 1.0%
Residue on Ignition NMT 0.5%
Heavy Metals NMT 20 ppm
pH (1% Solution) 2.0 – 4.0
Individual Impurity NMT 0.5%
Water Content NMT 1.0%
Melting Point 168°C – 172°C
Get Bulk Quote via WhatsApp